Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6762)
All Articles published online
|
Publishing Process of This Article
|
Jun 28, 2015 (publication date) through May 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7(12): 1685-1693 [PMID: 26140088 DOI: 10.4254/wjh.v7.i12.1685] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i12/1685.htm |
| Number | Citing Articles |
| 1 |
Masayuki Miyazaki, Masayoshi Yada, Kosuke Tanaka, Takeshi Senjyu, Takeshi Goya, Kenta Motomura, Motoyuki Kohjima, Masaki Kato, Akihide Masumoto, Kazuhiro Kotoh. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World Journal of Gastroenterology 2017; 23(29): 5379-5385 doi: 10.3748/wjg.v23.i29.5379
|
| 2 |
Tomomi Kogiso, Kuniko Yamamoto, Mutsuki Kobayashi, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Etsuko Hashimoto, Katsutoshi Tokushige. Ascites - Physiopathology, Treatment, Complications and Prognosis. 2017; doi: 10.5772/intechopen.69849
|
| 3 |
Tomomi Kogiso, Kuniko Yamamoto, Mutsuki Kobayashi, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Etsuko Hashimoto, Katsutoshi Tokushige. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites. Hepatology Research 2017; 47(9): 835 doi: 10.1111/hepr.12822
|
| 4 |
Hiroyuki Nakanishi, Masayuki Kurosaki, Takanori Hosokawa, Yuka Takahashi, Jun Itakura, Shoko Suzuki, Yutaka Yasui, Nobuharu Tamaki, Natsuko Nakakuki, Hitomi Takada, Mayu Higuchi, Yasuyuki Komiyama, Tsubasa Yoshida, Kenta Takaura, Tsuguru Hayashi, Konomi Kuwabara, Sei Sasaki, Namiki Izumi. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. Journal of Gastroenterology 2016; 51(6): 620 doi: 10.1007/s00535-015-1143-3
|
| 5 |
Toshiyuki Tahara, Kiyoto Mori, Mari Mochizuki, Ryoko Ishiyama, Marin Noda, Hitomi Hoshi, Alan Lefor, Satoshi Shinozaki. Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis. Biomedical Reports 2017; doi: 10.3892/br.2017.1005
|
| 6 |
Makoto Segawa, Isao Sakaida. Clinical Investigation of Portal Hypertension. 2019; : 501 doi: 10.1007/978-981-10-7425-7_51
|
| 7 |
Uday Sanglodkar, Mayank Jain, Jayanthi Venkataraman. A clinical audit of diuretic use in a cohort of patients with decompensated chronic liver disease in South India. Gastroenterology, Hepatology and Endoscopy Practice 2023; 3(1): 17 doi: 10.4103/ghep.ghep_28_22
|
| 8 |
Hideto Kawaratani, Hiroshi Fukui, Kei Moriya, Ryuichi Noguchi, Tadashi Namisaki, Masakazu Uejima, Mitsuteru Kitade, Kosuke Takeda, Yasushi Okura, Kosuke Kaji, Norihisa Nishimura, Hiroaki Takaya, Yousuke Aihara, Yasuhiko Sawada, Shinya Sato, Kenichiro Seki, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatology Research 2017; 47(9): 854 doi: 10.1111/hepr.12826
|
| 9 |
Yasuyuki Komiyama, Masayuki Kurosaki, Hiroyuki Nakanishi, Yuka Takahashi, Jun Itakura, Yutaka Yasui, Nobuharu Tamaki, Hitomi Takada, Mayu Higuchi, Tomoyuki Gotou, Youhei Kubota, Kenta Takaura, Tsuguru Hayashi, Wann Oh, Mao Okada, Nobuyuki Enomoto, Namiki Izumi, Han-Chieh Lin. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PLOS ONE 2017; 12(3): e0174649 doi: 10.1371/journal.pone.0174649
|
| 10 |
Koji Takagi, Naoki Sato, Shiro Ishihara, Michiko Sone, Hideo Tokuyama, Kenji Nakama, Toshiya Omote, Arifumi Kikuchi, Masahiro Ishikawa, Kenichi Amitani, Naoto Takahashi, Yuji Maruyama, Hajime Imura, Wataru Shimizu. Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria. Heart and Vessels 2018; 33(4): 413 doi: 10.1007/s00380-017-1066-4
|
| 11 |
Ioannis Bellos, Konstantinos Kontzoglou, Despina N Perrea. Predictors of tolvaptan short‐term response in patients with refractory ascites: A meta‐analysis. Journal of Gastroenterology and Hepatology 2020; 35(2): 182 doi: 10.1111/jgh.14784
|
| 12 |
Brett Fortune, Andres Cardenas. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterology Report 2017; 5(2): 104 doi: 10.1093/gastro/gox010
|
| 13 |
Masato Nakai, Koji Ogawa, Rei Takeda, Masatsugu Ohara, Naoki Kawagishi, Takaaki Izumi, Machiko Umemura, Jun Ito, Takuya Sho, Goki Suda, Kenichi Morikawa, Naoya Sakamoto. Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. Hepatology Research 2018; 48(3) doi: 10.1111/hepr.12988
|
| 14 |
Yasunari Hiramine, Hirofumi Uto, Yasushi Imamura, Takuya Hiwaki, Takeshi Kure, Sho Ijuin, Kohei Oda, Seiichi Mawatari, Kotaro Kumagai, Koki Tokunaga, Hirofumi Higashi, Ichiro Kanetsuki, Osamu Kubozono, Shigeho Maenohara, Akio Ido. Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema. Hepatology Research 2017; 47(6): 542 doi: 10.1111/hepr.12778
|
| 15 |
Michitaka Imai, Toru Ishikawa, Yuichi Kojima, Motoi Azumi, Yujiro Nozawa, Tomoe Sano, Akito Iwanaga, Terasu Honma, Toshiaki Yoshida. Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 2021; 33(1S): e161 doi: 10.1097/MEG.0000000000001985
|
| 16 |
Y Suzuki, A Naganuma, T Hoshino, T Hatanaka, T Ueno, M Namikawa, D Takizawa, H Arai, H Suzuki, H Takagi, H Tojima, Y Yamazaki, K Sato, S Kakizaki, T Uraoka. Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study. Acta Gastro Enterologica Belgica 2021; 84(1): 57 doi: 10.51821/84.1.357
|
| 17 |
Masato Nakai, Goki Suda, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto. Durable response without recurrence to Tolvaptan improves long-term survival. Journal of Gastroenterology 2020; 55(12): 1150 doi: 10.1007/s00535-020-01721-8
|
| 18 |
Tomoharu Yamada, Takamasa Ohki, Yuki Hayata, Yuki Karasawa, Satoshi Kawamura, Daisaku Ito, Kentaro Kojima, Michiharu Seki, Nobuo Toda, Kazumi Tagawa. Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis. Clinical Drug Investigation 2016; 36(10): 829 doi: 10.1007/s40261-016-0434-7
|
| 19 |
Masayuki Kurosaki, Namiki Izumi. Tolvaptan for the Treatment of Refractory Ascites. Internal Medicine 2016; 55(20): 2909 doi: 10.2169/internalmedicine.55.7556
|
| 20 |
Patricia Huelin, Jose Ignacio Fortea, Javier Crespo, Emilio Fábrega. Ascites - Physiopathology, Treatment, Complications and Prognosis. 2017; doi: 10.5772/intechopen.70384
|
| 21 |
Yoshitaka Arase, Tatehiro Kagawa, Kota Tsuruya, Hirohiko Sato, Erika Teramura, Kazuya Anzai, Shunji Hirose, Ryuzo Deguchi, Koichi Shiraishi, Tetsuya Mine. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clinical Drug Investigation 2019; 39(1): 45 doi: 10.1007/s40261-018-0714-5
|